NON-SMALL CELL & SMALL CELL LUNG CANCER

Advanced Lung Cancer Care in China

Lung cancer requires swift, precise treatment tailored to the tumor’s genetic makeup. China’s national cancer hospitals treat the largest number of lung cancer patients globally. This massive experience has led to world-class robotic surgeries that save healthy lung tissue, gentle particle radiation that protects the heart, and immediate access to the latest targeted pills and immune therapies.

  • Non-Small Cell & Small Cell Lung Cancers at All Stages
  • Tumors with Genetic Mutations (EGFR, ALK, KRAS, ROS1, and Others)
  • Advanced or Inoperable Cases Seeking Tumor-Shrinking Treatments
  • National Cancer Centers with Expert Multi-Doctor Review Boards
  • Gentle Particle Beams & Minimally Invasive Robotic Keyhole Surgery
  • Full English-Speaking Bedside Medical Guidance from Day One

SURGICAL, RADIATION & TARGETED INNOVATIONS

Key Lung Cancer Treatments in China

Advanced targeted therapies, robotic keyhole surgeries, and pinpoint proton & carbon ion radiation.

Proton & Carbon Ion Radiation

Ultra-precise particle radiation that stops exactly inside the tumor, killing cancer cells while sparing the heart and healthy surrounding lung tissue.
Learn More

Targeted Pills & Bispecifics

Rapid access to next-generation targeted medications and dual-action immune antibodies designed to overcome drug resistance when earlier treatments stop working.
Learn More

Robotic Keyhole Surgery

Gentle robotic surgery through tiny incisions that safely removes the tumor while preserving maximum breathing capacity and speeding recovery.
Learn More

WHY CHOOSE US

Why Choose China Cancer Help for Lung Cancer Care

A specialized clinical continuum connecting international lung cancer patients directly with China’s national thoracic centers.

China’s designated National Cancer Centers treat the world’s highest annual volume of complex thoracic malignancies. This immense clinical experience translates into exceptional surgical radicality, groundbreaking multi-target clinical trials, and early clinical availability of next-generation EGFR/ALK inhibitors and novel PD-1 bispecific antibodies (such as Ivonescimab) that show superior progression-free survival in advanced lung cancer.

Before traveling, your pathology reports, imaging scans, and molecular NGS panels are evaluated remotely by senior thoracic surgeons, pulmonologists, and particle radiation physicists. Every hospital service is billed transparently at public institution rates with no third-party markups, supported by dedicated bilingual medical coordinators throughout your hospital stay.

CASE EVALUATION PATHWAY

A Structured Pathway from Records to Care

A transparent, four-stage continuum connecting preliminary clinical evaluation to official hospital acceptance, specialized inpatient care, and ongoing continuity.

01. Submit Records Online

Upload pathology reports, biomarker NGS profiles, and imaging scans through our confidential clinical intake portal.

02. Remote MDT Review

National Clinical Research Center oncology boards evaluate eligibility, target expression, and formulate a customized protocol.

03. Visa & Admission

Receive official hospital medical invitation letters, transparent pricing schedules, and expedited department admission.

04. Treatment & Follow-up

Inpatient cellular or particle therapy in ISO-GMP cleanrooms with dedicated bilingual escorts and remote post-discharge care.

PATIENT FAQS

Frequently Asked Questions

Key clinical, financial, and logistical insights for international Lung Cancer patients considering advanced treatment in China.

Yes. China has rapid approval pathways for third- and fourth-generation EGFR, ALK, KRAS, and ROS1 inhibitors, as well as novel dual-action bispecific antibodies.
Particle radiation stops precisely inside the tumor without exiting behind it, protecting delicate heart muscle, the esophagus, and uninvolved lung tissue from unnecessary radiation.
Yes. Neoadjuvant combinations of targeted therapy or immunotherapy with chemotherapy frequently shrink large tumors, allowing surgeons to perform successful minimally invasive removal.
Initial remote case reviews by multidisciplinary thoracic tumor boards are completed within 48 hours upon receipt of digital CT/PET scans and pathology reports.

THORACIC ONCOLOGY PRE-ASSESSMENT

Request a Confidential Case Review for Lung Cancer

Submit your CT/PET scans, biopsy reports, and genetic testing results for a personalized review by China’s leading lung cancer specialists.

    Lung Cancer